Compare RGCO & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | PROF |
|---|---|---|
| Founded | 1912 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 243.2M |
| IPO Year | 2005 | 2017 |
| Metric | RGCO | PROF |
|---|---|---|
| Price | $22.93 | $6.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.70 | $12.00 |
| AVG Volume (30 Days) | 5.6K | ★ 63.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | 11.21 | ★ 25.89 |
| EPS | ★ 1.31 | 0.19 |
| Revenue | ★ $95,334,212.00 | $16,098,000.00 |
| Revenue This Year | $11.06 | $92.40 |
| Revenue Next Year | $2.89 | $64.10 |
| P/E Ratio | ★ $17.10 | $35.74 |
| Revenue Growth | 12.63 | ★ 50.73 |
| 52 Week Low | $19.68 | $3.92 |
| 52 Week High | $24.50 | $8.95 |
| Indicator | RGCO | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 46.15 |
| Support Level | $20.95 | $6.54 |
| Resistance Level | $24.06 | $7.07 |
| Average True Range (ATR) | 0.82 | 0.29 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 55.75 | 35.67 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.